Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 17/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.39 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12819019 | 0.93 | SLC2A1 (0.53) | SLC2A1SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL12818650 | 0.89 | SLC2A1 (0.59) | SLC2A1 | |
| SCHEMBL12819195 | 0.84 | SLC2A1 (0.55) | SLC2A1SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL12818250 | 0.82 | SLC2A1 (0.55) | SLC2A1SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL12818614 | 0.82 | SLC2A1 (0.50) | SLC2A1KDM4EHTT | |
| SCHEMBL12818859 | 0.81 | SLC2A1 (0.61) | SLC2A1KDM4EHTTSLC2A3SLC2A4 | |
| SCHEMBL12818437 | 0.80 | SLC2A1 (0.56) | SLC2A1SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL12818892 | 0.80 | SLC2A1 (0.59) | SLC2A1SMN1; SMN2KDM4EALDH1A1HTT | |
| SCHEMBL12819173 | 0.80 | SLC2A1 (0.50) | SLC2A1KDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL12818943 | 0.79 | SLC2A1 (0.60) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM TECHNOLOGY TRANSFER GMBH (DE) | 2014-08-07 | — | — | US | claimed |
| EP-2691392-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM Technology Transfer GmbH (DE) | 2014-02-05 | — | — | EP | claimed |
| WO-2012130322-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | ELARA PHARMACEUTICALS GMBH (DE) | 2012-10-04 | — | — | WO | claimed |
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM TECHNOLOGY TRANSFER GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| EP-2691392-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM Technology Transfer GmbH (DE) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012130322-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | ELARA PHARMACEUTICALS GMBH (DE) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | HIF1A, HIF1AN, EGLN3 | SLC2A1 1235/4885SMN1; SMN2 3227/4885KDM4E 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.